Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors by Shimizu, Toshio, LoRusso, Patricia M, Papadopoulos, Kyri P, Patnaik, Amita, Beeram, Muralidhar, Smith, Lon S, Rasco, Drew W, Mays, Theresa A, Chambers, Glenda, Ma, Anna, Wang, Jing, Laliberte, Robert, Voi, Maurizio, Tolcher, Anthony W

Get full text

Abstract CT056: A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate by Lakhani, Nehal, Chandana, Sreenivasa, Tolcher, Anthony, Cole, Yvette, Rivas, Karla, Sinclair, Sandra, Nadler, Paul I., Wood, Debra L., Papadopoulos, Kyri P.

Get full text

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors by Melear, Jason, Lakhani, Nehal, O'Shaughnessy, Joyce A, Wilks, Sharon T, Khan, Saad, Chandana, Sree R, Tolcher, Anthony W, Papadopoulos, Kyri P, Cole, Yvette, Rivas, Karla, Ghosh, Ria, Sinclair, Sandra, Lutz, Robert, Nadler, Paul I, Wood, Debra L, Burtness, Barbara

Get full text

Novel targeted therapies for advanced esophageal cancer by Lin, C.-C., Papadopoulos, K. P.

Get full text

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer by Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulous, Kyri, Rasco, Drew, Beeram, S. Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David

Get full text

Abstract A103: Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malign... by Tolcher, Anthony, Papadopoulos, Kyri, Agnew, Jim, Marshall, John, Tanzola, Carolyn, Zanghi, Jim, Baker, Kevin P., Keer, Harold N., Patniak, Amita

Get full text